Methods of oligosaccharide profiling for the detection of cancer
AssigneeThe Regents of the University of California
InventorsCarlito B. Lebrilla, Hyun Joo An, Kit S. Lam, Suzanne Miyamoto
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for identifying oligosaccharides specific to cancer and methods for determining a strain of cancer in an individual. The present invention also provides methods for diagnosing cancer or a stage of cancer in an individual by detecting the presence or absence of specific cancer markers and methods for treating cancer by administering antibodies directed to such markers. In addition, the present invention provides cancer markers comprising O-linked oligosaccharides and kits for diagnosing or treating cancer.
Claims26
A method for determining a stage, type, or strain of cancer in an individual, said method comprising:
- (a) obtaining a mass spectrum of oligosaccharides from a plurality of glycoproteins in a serum sample from said individual using MALDI-FTMS, wherein the oligosaccharides have been selectively released from said plurality of glycoproteins;
- and
- (b) comparing the mass spectrum of said oligosaccharides to a mass spectrum profile of oligosaccharides from at least one known stage, type, or strain of cancer,
- wherein said stage, type, or strain of cancer is determined by a similarity between the mass spectrum of said oligosaccharides and the mass spectrum profile of oligosaccharides from said at least one known stage, type, or strain of cancer.
The method of 1, wherein said strain of cancer is a strain of ovarian cancer or breast cancer.
The method of 1, wherein said stage of cancer is a stage of ovarian cancer or breast cancer.
A method for diagnosing cancer in an individual, said method comprising:
- (a) obtaining a mass spectrum of oligosaceharides from a plurality of glycoproteins in a serum sample from said individual using MALDI-FTMS, wherein the oligosaceharides have been selectively released from said plurality of glycoproteins;
- and
- (b) comparing the mass spectrum of said oligosaccharides to a mass spectrum profile of oligosaccharides from a control sample,
- wherein said control sample is a sample from a normal cell line or an individual not having cancer, and
- wherein a higher ratio of NeuGc-containing O-linked oligosaccharides to NeuAc-containing O-linked oligosaccharides in the mass spectrum of said oligosaccharides relative to the mass spectrum profile of oligosaccharides from said control sample indicates that said individual has cancer.
A method for diagnosing cancer in an individual, said method comprising:
- (a) obtaining a mass spectrum of oligosaccharides from a plurality of glycoproteins in a serum sample from said individual, wherein the oligosaccharides have been selectively released from said plurality of glycoproteins;
- and
- (b) determining the presence or absence of a cancer marker selected from the group consisting of a sulfated oligosaccharide, an N-acetylneuraminic acid (NeuAc)-containing oligosaccharide, an N-glycolylneuraminic acid (NeuGc)-containing oligosaccharide, a neutral oligosaceharide, a hexose (Hex)-containing oligosaceharide, a hexuronic acid (HexA)-containing oligosaceharide, and combinations thereof in the mass spectrum of said oligosaccharides,
- wherein the presence of said cancer marker indicates that said individual has cancer.
A method for diagnosing a stage of cancer in an individual, said method comprising:
- (a) obtaining a mass spectrum of oligosaccharides from a plurality of glycoproteins in a serum sample from said individual, wherein the oligosaccharides have been selectively released from said plurality of glycoproteins;
- (b) determining the presence or absence of a first cancer marker in the mass spectrum of said oligosaccharides, wherein said first cancer marker is selected from the group consisting of 1 HexNAc:1 Hex:1 NeuAc;
- 2 HexNAc:1 NeuAc:1 Fuc;
- 1 HexNAc:3 Hex:1 NeuAc;
- 1 HexNAc:2 Hex:1 NeuGc;
- 3 HexNAc:1 NeuGe;
- 1 HexNAc:2 Hex:1 NeuGc:1 Fuc;
- 1 HexNAc:3 Hex:1Fuc:1 SO3H;
- 2 HexNAc:1 Hex:2 Fuc:1 SO3H;
- 2 HexNAc:3 Hex:1 SO3H;
- 4 HexNAc:1 Hex:1 SO3H;
- 5 HexNAc:1 Hex:1 Fuc:1 SO3H;
- 2 HexNAc:2 Fuc;
- 2 HexNAc:1 Hex:1 Fuc;
- 4 HexNAc;
- 4 HexNAc:1 Hex;
- 1 HexNAc:3 Hex:2 Fuc;
- 1 HexNAc:4 Hex:1 Fuc;
- 3 HexNAc:
- 1 Hex:2 Fuc;
- 2 HexNAc:4 Hex:
- 1 Fuc;
- and combinations thereof;
- and
- (c) determining the presence or absence of a second cancer marker in the mass spectrum of said oligosaccharides, wherein said second cancer marker is selected from the group consisting of 1 HexNAc:2 Hex:1 NeuAc;
- 2 HexNAc:1 Hex:1 NeuAc;
- 3 HexNAc:1 Hex:1 NeuAc:3 Fuc;
- 1 HexNAc:1 Hex:1 NeuGc:1 Fuc;
- 2 HexNAc:1 NeuGc:1 Fuc;
- 3 HexNAc:4 Hex:1 NeuGc;
- 1 HexNAc:1 Hex:1 SO3H;
- 2 HexNAc:2 Hex:2 Fuc:1 SO3H;
- 1 HexNAc:2 Fuc;
- 1 HexNAc:2 Hex:2 Fuc;
- 6 HexNAc;
- 3 HexNAc:3 Hex:2 Fuc;
- 4 HexNAc:3 Hex:1 Fuc;
- and combinations thereof,
- wherein the presence of said first cancer marker and the absence of said second cancer marker indicates that said individual has an early, stage cancer and wherein the presence of said second cancer marker indicates that said individual has a late stage cancer.
A method for diagnosing cancer in an individual, said method comprising:
- (a) obtaining a mass spectrum of oligosacoharides from a plurality of glycoproteins in a serum sample from said individual using MALDI-FTMS, wherein the oligosaccharides have been selectively released from said plurality of glycoproteins;
- (b) comparing the mass spectrum of said oligosaceharides to a mass spectrum profile of oligosaceharides from a cancer sample;
- and
- (c) diagnosing cancer by a similarity between the mass spectrum of said oligosaccharides and the mass spectrum profile of oligosaccharides from said cancer sample.
Dependencies are inferred from the claim text.